EGFR and non-small cell lung carcinoma: In a randomized, open-label, phase 3 trial (ARCHER 1050), dacomitinib statistically significantly improved progression-free survival and overall survival versus gefitinib, a first-generation EGFR tyrosine kinase inhibitor, as a first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) [3,4,5].